Category Archives: Muscular Dystrophy Treatment

NEWPORT BEACH, Calif., Sept. Continue reading →

NEWPORT BEACH, Calif., Sept. Continue reading →

September 22, 2020 01:00 ET | Source: Santhera Pharmaceuticals Holding AG multilang-release Pratteln, Switzerland, September22, 2020 Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data on the safety, tolerability and efficacy of vamorolone in patients with Duchenne muscular dystrophy (DMD). These 18-month treatment data extend previously published 24-week treatment data, and show a reduction of corticosteroid-specific side effects and sustained efficacy with vamorolone including clinical improvement through the 18-month follow-up period Continue reading →

Sarepta Therapeutics Inc. (NASDAQ:SRPT) has announced the completion of a Type C written response only meeting with the FDAs Centre for Biologics Evaluation and Researchs (CBER) Office of Tissues and Advanced Therapies(OTAT) for SRP-9001. Continue reading →

September 23, 2020 09:25 ET | Source: Capricor Therapeutics --Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD) Continue reading →

As per the report by Persistence Market Research (PMR), the globalduchenne muscular dystrophy marketis expected to experience strong growth. The market is also estimated to expand at a CAGR of 48.3% during the forecast period. The global duchenne muscular dystrophy market is estimated to bring in US$ 10,664.5 million revenue by the end of 2026. Continue reading →

MISSOULA - The coronavirus pandemic has lead a lot of events to turn virtual and the Missoula Rural Fire District's 'Fill the Boot' fundraiser is no exception. Due to COVID-19, firefighters are still trying to fill the boot, however, this year it will be done online. Continue reading →

Max Adler is national ambassador for the Walk & Roll to Cure FSHD LEXINGTON, Mass. (PRWEB) August 25, 2020 The FSHD Society, a 501c3 nonprofit patient advocacy organization, announced today that Max Adler, an actor best known for his roles on the hit series Glee, available for streaming on Netflix, and Switched at Birth, is serving as this years national ambassador for the organizations signature fundraiser, Walk & Roll to Cure FSHD, taking place September 12. There are currently no treatments available to people with FSHD and with Max Adlers help the FSHD Society is hoping to raise $500,000 to be put towards research and drug development with the goal of having an approved therapy by 2025. Continue reading →

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Oculopharyngeal Muscular Dystrophy Treatment market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Oculopharyngeal Muscular Dystrophy Treatment market Continue reading →

Text size Newly-hired analyst Danielle Brill launched coverage at Raymond James this week with a 490-page survey of her favorite biotech stocks. Atop the list are hematology drugmaker Acceleron Pharma and the gene therapy developer uniQure. Brill thinks Acceleron (ticker: XLRN) could rise at least 60%, while uniQure (QURE) could nearly double. Continue reading →